Urogen Pharma Ltd (NASDAQ:URGN) Expected to Announce Earnings of -$1.20 Per Share

Equities analysts forecast that Urogen Pharma Ltd (NASDAQ:URGN) will post earnings of ($1.20) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Urogen Pharma’s earnings. The highest EPS estimate is ($1.11) and the lowest is ($1.33). Urogen Pharma reported earnings per share of ($1.14) during the same quarter last year, which would suggest a negative year-over-year growth rate of 5.3%. The business is scheduled to announce its next earnings report on Tuesday, August 13th.

On average, analysts expect that Urogen Pharma will report full-year earnings of ($5.37) per share for the current year, with EPS estimates ranging from ($5.83) to ($4.82). For the next year, analysts expect that the company will report earnings of ($4.23) per share, with EPS estimates ranging from ($6.33) to ($1.66). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Urogen Pharma.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.12) by $0.01. Urogen Pharma had a negative return on equity of 61.24% and a negative net margin of 4,296.08%.

A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Urogen Pharma from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Saturday, May 11th. Cowen restated a “buy” rating on shares of Urogen Pharma in a report on Monday, May 6th. Oppenheimer restated a “buy” rating on shares of Urogen Pharma in a report on Tuesday, March 19th. Stifel Nicolaus restated a “buy” rating and issued a $63.00 target price on shares of Urogen Pharma in a report on Tuesday, March 5th. Finally, Raymond James set a $57.00 target price on Urogen Pharma and gave the company a “buy” rating in a report on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $59.50.

NASDAQ URGN traded up $0.15 on Monday, hitting $35.40. 8,395 shares of the stock traded hands, compared to its average volume of 136,165. The company has a 50-day moving average price of $36.89. Urogen Pharma has a twelve month low of $33.37 and a twelve month high of $56.91. The stock has a market capitalization of $484.69 million, a P/E ratio of -7.33 and a beta of 1.31.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado bought a new stake in Urogen Pharma during the 1st quarter worth about $41,000. Parallel Advisors LLC boosted its holdings in Urogen Pharma by 100.0% in the 4th quarter. Parallel Advisors LLC now owns 1,000 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Urogen Pharma by 100.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock valued at $74,000 after purchasing an additional 1,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Urogen Pharma by 112.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after purchasing an additional 1,282 shares during the period. Finally, Van ECK Associates Corp boosted its holdings in Urogen Pharma by 27.6% in the 4th quarter. Van ECK Associates Corp now owns 4,364 shares of the company’s stock valued at $188,000 after purchasing an additional 944 shares during the period. 97.86% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Read More: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.